Latest News - AMD

Wednesday, July 19, 2017 | Clinical Trials, AMD, BioTime

Data From BioTime’s Phase 1/2a OpRegen Trial to be Presented at the 2017 AAO Annual Meeting

BioTime announced that an abstract related to the company’s retinal tissue implant has been accepted for a paper presentation at the American Academy of Ophthalmology (AAO) annual meeting being …

Read the full story

Friday, July 14, 2017 | Clinical Trials, AMD

Spark Therapeutics Announces Publication of Pivotal Phase 3 Clinical Trial Data for Investigational Voretigene Neparvovec

Gene therapy company Spark Therapeutics announced that The Lancet has published phase 3 clinical trial data of voretigene neparvovec, an investigational, potential one-time gene therapy candidate for …

Read the full story

Friday, June 30, 2017 | Medical Studies, AMD

An Eye to Health: Diet and Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is a leading cause of vision loss in the developed world, with advanced AMD affecting approximately 2 million people in the United States.[1,2] AMD is characteri…

Read the full story

Friday, June 30, 2017 | Retina, AMD

Nightstar Raises $45 Million to Fund Development of Gene Therapies for Blinding Retinal Diseases

NightstaRx announced the completion of a $45 million Series C financing transaction, the proceeds of which will be used for the upcoming phase 3 trial for Nightstar’s lead product candidate, NSR…

Read the full story

Thursday, June 29, 2017 | Medical Studies, Retina, AMD

Risk of Age-related Macular Degeneration Higher With Myeloproliferative Neoplasms

Patients with chronic myeloproliferative neoplasms (MPNs) have an increased risk of age-related macular degeneration (AMD), according to a Danish registry study. "Blood cancers, which most recent…

Read the full story

Wednesday, June 28, 2017 | Product Releases, AMD

MacuLogix Announces Communication Guide for Eye Care Professionals Who Diagnose and Treat AMD

MacuLogix released a step-by-step communication guide for eye care professionals treating patients with AMD. MacuLogix collaborated with Laurie Sorrenson, OD, to develop its “12 Ways to Turn an …

Read the full story

Tuesday, June 27, 2017 | Product Releases, AMD, OD-OS GmbH

OD-OS Launches Prepanned PRP for its Navilas Laser System

OD-OS announced the market release of its preplanned panretinal photocoagulation (PRP) capability for Navilas 577s. Preplanned PRP allows the physician to lay out the treatment strategy for the periph…

Read the full story

Thursday, June 22, 2017 | Clinical Trials, Retina, AMD

RXi Pharmaceuticals Announces Completion of Enrollment of Phase 1/2 Clinical Trial with RXI-109 for Retinal Scarring

RXi Pharmaceuticals announced the completion of enrollment in its phase 1/2 study RXI-109-1501. This multicenter, multidose, dose escalation trial is being conducted in patients with advanced neovascu…

Read the full story

Wednesday, June 21, 2017 | Medical Studies, AMD

International Academy of Low Vision Specialists Recognizes the Mental Health Changes That May Come with a Diagnosis of AMD

The diagnosis of low vision due to age, such as macular degeneration, often comes with more consequences than just the inability to see. A new study by the National Eye Institute (NEI) reports that pa…

Read the full story

Tuesday, June 20, 2017 | Clinical Trials, AMD, Novartis

Novartis RTH258 (Brolucizumab) Demonstrates Robust Visual Gains in Wet AMD Patients with a Majority on a 12-week Injection Interval

Novartis reported that RTH258 (brolucizumab) 6 mg met the primary and key secondary endpoints in two phase 3 studies, HAWK and HARRIER. RTH258 3 mg, evaluated in HAWK, also met these endpoints. These …

Read the full story

Thursday, June 15, 2017 | Medical Studies, Retina, AMD

Aflibercept May Be Effective for Resistant Exudative AMD

Aflibercept appears to improve outcomes in patients with exudative age-related macular degeneration (AMD) resistant to treatment with ranibizumab or bevacizumab, researchers from Norway report. "…

Read the full story

Monday, February 06, 2017 | Acquisitions/Mergers, AMD

BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Retinal Disease Therapy From University of Pittsburgh Medical Center

BioTime announced the acquisition of global rights to ophthalmology-related intellectual property assets from the University of Pittsburgh’s Medical Center (UPMC), via the school’s Innovat…

Read the full story

Friday, February 03, 2017 | Medical Studies, Retina, AMD

Dexamethasone Implant With Anti-VEGF Explored for Wet AMD

Used in combination with antivascular endothelial growth factor (anti-VEGF) therapy, dexamethasone implants (0.7 mg Ozurdex, Allergan) may help some patients with neovascular age-related macular degen…

Read the full story

Thursday, February 02, 2017 | Clinical Trials, AMD, Genentech

Genentech Completes Patient Enrollment in Two Large Phase 3 Studies for Lampalizumab

Genentech has completed enrollment in two large phase 3 clinical trials, Chroma and Spectri, investigating the efficacy and safety of lampalizumab in reducing the progression of geographic atrophy (GA…

Read the full story

Wednesday, February 01, 2017 | Management/Leadership, AMD, Ophthotech

Ophthotech Announces Strategic Review Plan

Ophthotech announced that it has initiated a plan to review its strategic alternatives in order to maximize shareholder value. Without limiting any option, the principal focus of this plan is to activ…

Read the full story
Load More